Cardiff Oncology, Inc. Common Stock
$1.30
-$0.05 (-3.70%)
$1.26Day Range$1.38
Key Statistics
Market Cap
$105.02M
Shares Outstanding
77.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 22, 1997
Round Lot
100
Locale
US
Trading Data
Day Open
$1.36
Day High
$1.38
Day Low
$1.26
Volume
1.13M
VWAP
$1.30
Prev Close
$1.35
Transactions
--
Acc. Volume
--
About Cardiff Oncology, Inc. Common Stock
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283631 employees11055 FLINTKOTE AVENUE, SAN DIEGO, CA, 92121858-952-7570IPO May 22, 1997US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001213037
- Composite FIGI
- BBG000PXLKM7
- Share Class FIGI
- BBG001SLWWP7
- Ticker Root
- CRDF
- SIC Code
- 2836
About Cardiff Oncology, Inc. Common Stock (CRDF) Stock
Cardiff Oncology, Inc. Common Stock (CRDF) closed the 2026-09-17 session at $1.30, down 3.70% versus the previous close (-0.05). The stock opened at $1.36 and traded between $1.26 and $1.38 during that session. Session trading volume was 1.1M shares. The volume-weighted average price (VWAP) is $1.30.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Cardiff Oncology, Inc. Common Stock has a market capitalization of $105.0 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. CRDF is listed on the XNAS exchange. The company employs approximately 31 people. Cardiff Oncology, Inc. Common Stock is headquartered in SAN DIEGO, CA. The recorded listing date is 1997-05-22.
On this page you can find market CRDF stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.